DXY, EUR/USD, USD/JPY, GBP/USD, AUD/USD, USD/CAD
HELIOS AND MATHESON ANALYTICS INC, SPDR S&P 500, BANK OF AMERICA CORPORATION, ADVANCED MICRO DEVICES, INC., SPDR SELECT SECTOR FUND - FINANCIAL, ISHARES MSCI EMERGING INDEX FUND
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
Gold, Silver, Crude Oil, Natural Gas, Corn, Bitcoin
BTC/USD, ETH/USD, BCH/USD, XRP/USD, LTC/USD, ETC/USD
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
First I'm going to admit my last attempt at the stock was poorly timed -- I was a pawn being manipulated by the market forces. But, I think now, with 200-sma support, and better trendline support, this might still be a good trade. Might be at the caliber of a bishop or knight strategic entry now. My only criteria is it needs to trade above yesterday's high, so, ...
Cheap stock with with a pretty relevant business for today. Thinking it has a move higher soon.
Everytime AMEX:XXII goes up a little bit everybody takes profit and we return where we are. This stock is underperforming because of that. I wouldn't be surprised if it goes down tomorrow day time!
Price has been consistently bouncing off of this trendline support. I think we push up from here.
Following support, I predict this will break through the ceiling and continue up. Medium - long term
Market settling down and XXII poised for recovery at 0.236 Fib entry of $3.25.
Not good if it goes below this.
Wait for CCI to turn upward -150 range, likely within next day trading.
Look for resistance to break upward in next week for next area most likely 0.5 (2.50).
Solid stock for nicotine free tobacco and acquisition candidate.
Cannabis stocks started ...
22nd Century Group is a little biotech developing technology which allows the increase or decrease in the level of nicotine and other nicotinic alkaloids in tobacco plants. The company also has the technology to control levels of cannabinoids in cannabis plants.
The shares have appreciated lately, which is a normal occurrence for a news-driven stock. XXII has ...
XXII is a plant bio tech company that specialize in the development of allowing the increase or decrease in the level of nicotine in tobacco as well as the levels of cannabinoids in cannabis plants. This development is through genetic engineering. The company was established Jan 25 2011 and is in NY.
Products include X-22, spectrum government research ...
Long to where everything meets, then profit taking.
XXII looks like a possible bounce off support around $2.00 Had a nice bullish day closing at $2.13 (HOD) or +3.9% RSI is oversold, has plenty of room to reach the bullish range. Next price target is $2.20 and we want to see it break the downtrend line. If it can break above that and hold above $2.20 we could possibly see $2.40 next.
Setting up to buy XXII at the .618 retrace of the break of double bottom structure
Chart set up is there this has potential to go up, and recent FDA news can be good for the company
Correction of the extended third wave of the extended third wave looks completed
Technically all indicators are looking very bearish.
MFI 14 52.67 (Money returning into stock and above 50). MACD cross above trigger line (Look at the last time the MACD crossed at this level). RSI 14 50.36 (Bullish 50 line crossover). Within Upper BB with support from 2.78 - 2.69. Pullback today after several up days. Still within trend line. Possible FDA ANPRM issued next week on mandates on nicotine levels in ...
XXII Reversal trend. Back within trend line. MFI 10 above 50. RSI 14 above 50. MACD cross over trigger line. Potential FDA ANPRM released in several days in regards to lower nicotine levels in US Tobacco.
Potential reversal for XXII. MACD closer to trigger line and curl up. A lot of potential with XXII and looks as if this could be a reversal bounce off 200 SMA.
Great opportunity with 22nd Century Group. Potential reversal bounce off 200 SMA and positive divergence on MFI 14. Many things in the works right now with XXII. Phase 3 peer review soon, ANRPN from FDA on VLN tobacco, and increased institutional investment in Q4 2017.